| ISSN |
2218-4333 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Retrospective Study |
| Article Title |
Pathological response to neoadjuvant therapy with chemotherapy vs chemoradiotherapy in stage III NSCLC. Contribution of IASLC recommendations
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Diego Muñoz-Guglielmetti, David Sanchez-Lorente, Roxana Reyes, Daniel Martinez, Carmen Lucena, Marc Boada, Pilar Paredes, Marta Parera-Roig, Ivan Vollmer, Joel Mases, Roberto Martin-Deleon, Sergi Castillo, Mariana Benegas, Silvia Muñoz, Maria Mayoral, Carla Cases, Meritxell Mollà and Francesc Casas |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Diego Muñoz-Guglielmetti, MD, Doctor, Doctor, Radiation Oncology, Hospital Clínic de Barcelona, Carrer de Villarroel 170, Barcelona 08036, Cataluña, Spain. dimunoz@clinic.cat |
| Key Words |
Non-small cell lung cancer; Chemotherapy; Chemoradiotherapy; Neoadjuvant treatment; Resectable stage III; Pathological response |
| Core Tip |
Preoperative chemotherapy (Ch) has become a standard treatment option, especially in resectable stage III (primarily N2) non-small cell lung cancer (NSCLC). Phase II and phase III studies have raised the question as to whether preoperative Ch plus radiotherapy provides any additional benefits to preoperative Ch. The objective of our retrospective study was to contribute (with an experienced team of medical oncologists, radiation oncologists, thoracic surgeons, and pathologists) to the International Association for the Study of Lung Cancer recommendations in relation to differences in the pathological evaluation of tumors and mediastinal and hilar nodes in resectable stage III NSCLC, comparing neoadjuvant Ch vs chemoradiotherapy. |
| Publish Date |
2021-11-19 09:32 |
| Citation |
Muñoz-Guglielmetti D, Sanchez-Lorente D, Reyes R, Martinez D, Lucena C, Boada M, Paredes P, Parera-Roig M, Vollmer I, Mases J, Martin-Deleon R, Castillo S, Benegas M, Muñoz S, Mayoral M, Cases C, Mollà M, Casas F. Pathological response to neoadjuvant therapy with chemotherapy vs chemotherap-radiotherapy in stage III NSCLC. Contribution of IASLC recommendations. World J Clin Oncol 2021; 12(11): 1047-1063 |
| URL |
https://www.wjgnet.com/2218-4333/full/v12/i11/1047.htm |
| DOI |
https://dx.doi.org/10.5306/wjco.v12.i11.1047 |
